Palifermin
- Generic Name
- Palifermin
- Brand Names
- Kepivance
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 162394-19-6
- Unique Ingredient Identifier
- QMS40680K6
- Background
Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli.
Palifermin was granted FDA approval on 15 December 2004.
- Indication
For treatment of oral mucositis associated with chemotherapy and radiation therapy.
- Associated Conditions
- Oral Mucositis
- Associated Therapies
- -
Palifermin After Haploidentical PBSCT
- Conditions
- Interventions
- Locations
- 🇩🇪
Dr Ruth Seggewiss, Würzburg, Germany
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2009-03-02
- Lead Sponsor
- Swedish Orphan Biovitrum
- Registration Number
- NCT00540332
A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT
- Conditions
- Interventions
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2014-12-05
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 27
- Registration Number
- NCT00460421
- Locations
- 🇺🇸
University of Texas, Dallas, Texas, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Loma Linda University, Loma Linda, California, United States
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 145
- Registration Number
- NCT00410982
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer
- First Posted Date
- 2006-10-29
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 100
- Registration Number
- NCT00393822
Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
- First Posted Date
- 2006-09-15
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 99
- Registration Number
- NCT00376935
- Locations
- 🇺🇸
Hosp. of the Univ. of Pennsylvania CRS, Philadelphia, Pennsylvania, United States
🇺🇸IHV Baltimore Treatment CRS, Baltimore, Maryland, United States
🇺🇸Bmc Actg Crs, Boston, Massachusetts, United States
Palifermin DDI (Drug Drug Interaction)
- First Posted Date
- 2006-08-08
- Last Posted Date
- 2014-11-06
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 45
- Registration Number
- NCT00361348
Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2005-12-20
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT00267046
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 155
- Registration Number
- NCT00189488
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer
- First Posted Date
- 2005-08-19
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 241
- Registration Number
- NCT00131638
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.